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Background/aim: Data about contact allergen sensitization (CAS) in children with atopic dermatitis (AD) are limited. The purpose of
this study was to identify the frequency and patterns of CAS in children with AD by using a ready-to-use patch test system.
Materials and methods: After receiving the history of CAS in the patients, the severity of AD and IgE-mediated allergen sensitization
were determined.
Results: Of 134 children with AD, 33.8% (n = 45) had at least 1 positive reaction. The most frequent positive reaction was to nickel
sulfate (NS) (37.8%, 17/45), followed by methylchloroisothiazolinone (20.0%, 9/45) and thimerosal (15.6%, 7/45). The total Scoring
Atopic Dermatitis (SCORAD) score was significantly higher in the NS-sensitized group (P = 0.036). The patients with NS sensitization
had moderate–severe AD more frequently than those without any reaction (P = 0.020). When the SCORAD score was evaluated in
detail, extent of eczema, score of sleep loss, and pruritus were significantly higher in the patients with NS sensitization than those
without any reaction (P = 0.002, P = 0.001, and P = 0.002, respectively).
Conclusion: Our study confirms the necessity of CAS in the management of AD. In particular, NS sensitization should be considered
for children with severe AD or larger extent of eczema and trunk involvement.
Key words: Atopic dermatitis, children, contact allergen sensitization

1. Introduction
Allergic contact dermatitis is an underestimated health
problem in the pediatric population with atopic dermatitis
(AD) (1). There are limited studies in the literature about
the prevalence and clinical characteristics of allergic
contact sensitization and dermatitis in children with AD
(2–8). Allergic contact dermatitis is not rare in children
with AD (9); they are exposed to more sensitizers because
of the damaged epidermal barrier and the extensive use of
topical medications (10).
The patch test is accepted as the gold standard for
the detection of contact sensitization and allergy (11).
The test provides the ultimate diagnose of allergic
contact dermatitis, which is the result of delayed type
hypersensitivity reactions. Additionally, it may detect
contact sensitizations secondary to or complicating AD.
Different prevalence rates of contact allergens and
patterns of sensitization reported by different studies may
be due to variations in regional referral patterns, patch
* Correspondence: aysegul.akan@hotmail.com

testing selection criteria, and patch test material used (12).
Studies about contact dermatitis and allergen sensitization
in Turkish children are limited (13).
The aim of this study was to identify the frequency of
contact allergen sensitization (CAS) in children with AD,
the most common sensitizers, the relation with specific
comorbidities [coexisting asthma, allergic rhinitis, current
household smoking, prenatal smoking, immunoglobulin
E (IgE)-mediated allergic sensitization], and the rate of
clinical relevance of CAS in a group of patients at our
center.
2. Materials and methods
2.1. Patients
Children with AD treated at the Ankara HematologyOncology Children’s Research and Education Hospital,
Clinic of Pediatric Allergy, were enrolled in the study
between September 2011 and March 2012. After receiving
informed consent from the caregivers, the medical
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histories of the patients were evaluated for the status of
CAS. The clinical diagnosis of AD was made according to
the diagnostic criteria of Hanifin and Rajka (14). Patients
who had a limited area on the back for a patch test, and
those with comorbidities other than allergic diseases,
were not included in the study. Data on prenatal smoking,
current household smoking exposure, and family history
of allergic diseases were obtained from the caregivers
of the patients. All of the patients were evaluated for
coexisting allergic diseases other than AD (asthma and
allergic rhinitis). A skin prick test (SPT) for common food
(cow’s milk, egg white, wheat, peanut, soy, and fish) and
aeroallergens (house dust mite, cockroach, animal dander,
mold, and mixed grass pollen) was performed for all of the
patients. According to sensitization to common allergens
in the SPT, specific IgE tests were also performed. Total
serum IgE and percentage of peripheral blood eosinophil
tests were also performed for the whole study group. The
severity of AD was defined according to the Scoring Atopic
Dermatitis (SCORAD) score (15). The SCORAD index
consists of A, B, and C scores. The A score grades the
extent of eczema indicated as percent of the patient’s total
body surface, thus ranging between 0 and 100. The B score
is the definition and grading of intensity items. Six items
are selected: erythema, edema/papulation, oozing/crusts,
excoriations, lichenification, and dryness. Each item may be
graded from 0 to 3 (0 = absent, 1 = mild, 2 = moderate, 3 =
severe). Thus, the B score may range between 0 and 18. The
C score consists of subjective items such as sleep loss and
pruritus. The caregivers, or the patients older than 7 years
of age, were requested to rate each of the subjective items
from 0 to 10 (15). The patients were grouped as having mild,
moderate, or severe AD according to the cut-off points of
25 and 50 that had been defined before in the literature
for SCORAD scores (15,16). The variables were compared
for mild, moderate, and severe AD groups. Analyses were
repeated for a unified group of moderate and severe AD
cases. After this initial evaluation, a patch test was applied
to the back of the patients. The patients and the caregivers
were questioned about the presence of symptoms of contact
dermatitis both before and after patch testing.
2.2. Procedure of patch testing
Oral treatments with antihistamines and systemic steroids
were stopped 7 days before patch testing. The use of topical
steroids and topical immunomodulators was prohibited on
the test area for 7 days before patch testing. The presence
of sensitization for contact allergens was evaluated by
using a ready-to-use patch test system (TRUE test, Mekos
Laboratories AS, Hillerød, Denmark). It includes 29
standardized test substances including the most common
allergens or allergen mixes selected in accordance with the
recommendations of the International Contact Dermatitis
Research Group. Patch test plasters were applied on the
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upper back of the patients and removed after 2 days. The
first reading was performed on day 2 at least 20 min after
removing the patches. On day 3, the routine final reading
was made for all patients. If necessary, later readings on
days 5 and 7 were performed. The clinical relevance of
the positive reactions was considered if the patient or
the caregiver described symptoms related to cutaneous
exposure to a product known to contain the allergen to
which the patient had reacted.
2.3. Data analysis and statistical analysis
Results were expressed as percentile (absolute numbers),
as mean and standard deviation, or as median and
interquartile range (IQR) as required. SPSS 15.0 (SPSS
Inc., Chicago, IL, USA) was used for statistical analyses.
To compare variables, the chi-square test and Mann–
Whitney U test were used. A 2-tailed P-value of <0.05 was
considered statistically significant.
3. Results
3.1. Characteristics of the study group
The caregivers of 145 patients with AD were asked for
permission to enroll the patients in the study, and 134 of
them signed informed consent forms and accepted the
patch testing procedure. The average age of the study group
was 21 (9–59) months [median (IQR)], ranging between
2 and 206 months. Boys accounted for 58.1% (n = 79) of
the patients. Coexisting allergic diseases other than AD
(asthma and/or allergic rhinitis) were defined for 28.9%
(n = 39) of the patients, while 19.9% (n = 27) had family
history of allergic diseases. The median SCORAD index
was 29.5 (18–45.5). According to SCORAD scores, 38.2%
of the patients were grouped as having mild, 39.7% as
moderate, and 20.6% as severe AD. Regarding the results
of SPT and allergen specific IgE, 53.0% (n = 71) of the
study population had sensitization to common allergens.
Of these, 32.1% (n = 43) of patients had sensitization to
food and 26.1% (n = 35) to inhalant allergens.
Of the study group, 33.8% (n = 45) had at least 1
positive patch test reaction on the TRUE test. Sixteen
of them (35.6%) had more than 1 positive patch test
reaction. Only 1 patient described having symptoms of
contact dermatitis without a positive patch test reaction.
The most frequent positive patch test reaction was to
nickel sulfate (NS) (37.8%, 17/45), followed by reaction
to methylchloroisothiazolinone (MCI) (20.0%, 9/45) and
thimerosal (15.6%, 7/45). The other positive reactions
were 4 patients for black rubber mix; 3 patients for each of
potassium dichromate, cobalt chloride, p-tert butyl phenol
formaldehyde resin, and thiuram mix; 2 patients each
for neomycin sulfate, fragrance mix, formaldehyde, and
mercapto mix; 1 patient each for wool alcohols, colophony,
balsam of Peru, ethylenediamine dihydrochloride, paraben
mix, carba mix, quaternium-15, mercaptobenzothiazole,
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p-phenylenediamine, diazolidinyl urea, and tixocortol
21-pivalate. The frequency of the clinical relevance of
positive reactions was as follows: 7/17 of the patients
with positive reaction to NS, 5/9 of those with positive
MCI reaction, 2/7 with positive thimerosal reaction,
1/3 with positive potassium dichromate reaction, 1/2
with positive fragrance mix reaction, 1/1 with positive
colophony reaction, 1/1 with positive ethylenediamine
reaction, 1/3 with positive cobalt chloride reaction, 2/3
with positive p-tert butyl phenol formaldehyde resin
reaction, 1/1 with positive paraben mix reaction, 1/1
with positive quaternium-15 reaction, 1/2 with positive
mercapto mix reaction, and 1/1 with positive diazolidinyl
urea reaction had symptoms of contact dermatitis
related to patch test results. The positive reactions with
neomycin sulfate, balsam of Peru, carba mix, black rubber
mix,
mercaptobenzothiazole,
p-phenylenediamine,
formaldehyde, thiuram mix, and tixocortol 21-pivalate
were not related to any clinical symptoms. Of all patients

with positive patch test reactions, 40.0% (n = 18) had
symptoms related to the positive reaction on patch test.
3.2. Patients with and without positive patch test
reactions
There was no difference in the distribution or frequency
of age, sex, age of eczema onset, coexisting allergic
diseases, family history of allergic diseases, history of
current household smoking, total IgE, and percentage of
peripheral blood eosinophils between the groups with
and without positive patch test reactions. There were no
differences in the total SCORAD scores or in the frequency
of severity grade of AD. When the SCORAD score was
evaluated in detail, the scores of sleep loss and pruritus
were significantly higher in the group with a positive patch
test reaction than in patients without (P = 0.004 and P =
0.018, respectively) (Table 1).
Some of the substances on the TRUE test may be found
in emollients, antiseptics, cosmetics, and toiletries, such as
wool alcohols, neomycin sulfate, fragrance mix, colophony,

Table 1. Features of the patients with and without positive patch test reactions. Data are shown as percentiles
(absolute numbers) or medians (interquartile ranges), and statistically significant data are shown in bold.
Patch test reactions

Positive (n = 45)

Negative (n = 89) P

Age (months)*

15 (6–63)

24 (12–58)

0.255

Age of AD onset (month)*

5 (1–12)

9 (2–22)

0.218

Sex, male

0.470

62.2 (28)

55.7 (49)

Prenatal smoking†

11.1 (5)

6.8 (6)

0.404

Current household smoking†

44.4 (20)

52.3 (46)

0.393

†

Consumption of cow milk in the first year of life†

35.6(16)

33.0 (29)

0.764

Coexisting allergic disease (asthma, allergic rhinitis)†

22.2 (10)

32.2 (28)

0.231

Familial history of allergic diseases†

15.6 (7)

21.6 (19)

0.406

Food allergen†

33.3 (15)

30.7 (27)

0.756

Inhalant allergen†

17.8 (8)

29.5 (26)

0.141

IgE*

53 (18–125)

37 (16–190)

0.411

Percent of eosinophils*

3 (1–5)

4 (1–7)

0.139

62.2 (28)

61.4 (54)

0.923

Allergen sensitization

Localization of eczema
Face†
Trunk

37.8 (17)

22.7 (20)

0.067

Moderate–severe AD†

66.7 (30)

58.4 (52)

0.453

Total SCORAD score*

30 (21–48)

30 (16–42)

0.258

Extent of eczema (involved percent of total body surface)*

6 (4–16.5)

4 (2–8.8)

0.113

Score of B symptoms*

6 (3–9)

6 (3–9)

0.703

Score of sleep loss*

5 (0–8)

0 (0–5)

0.004

Score of pruritus*

8 (4–10)

6 (3–8)

0.018

†

* Median (interquartile range).
†
Percent (absolute number).
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balsam of Peru, ethylenediamine dihydrochloride, cobalt
chloride, formaldehyde resin, paraben mix, carba mix,
MCI, quaternium-15, formaldehyde, thimerosal, thiuram
mix, diazolidinyl urea, and tixocortol pivalate. Of the study
group, 25.4% (n = 34) patients had contact sensitization
to the ingredients of these products. Only 1 patient had
sensitization to tixocortol pivalate, but had no clinically
relevant symptoms. These patients had more than 1
positive reaction on patch tests more frequently than the
participants with positive reactions to other materials
that were not in these products (P = 0.009). There was
no difference in age, onset of AD, sex, coexisting allergic
diseases other than AD, severity of AD, and IgE mediated
allergen sensitization between the patients sensitized
to ingredients of these products and those sensitized to
other allergens in the TRUE test, or those without any
sensitization. There was no patient sensitized to steroids
like budesonide and hydrocortisone-17-butyrate.
3.3. Patients with NS sensitization
Of the study group, 12.7% (n = 17) of the patients were
sensitized to NS. The distribution and frequency of age,

sex, age of eczema onset, IgE, and percent of peripheral
blood eosinophils were similar for the patient group with
NS sensitization and those without patch test reaction.
Regarding the localization of eczema, trunk involvement
was significantly more frequent in the group with NS
sensitization than those without any patch test reaction (P
= 0.016) (Table 2). Total SCORAD score was significantly
higher in the NS-sensitized group (P = 0.036). The patients
with NS sensitization had moderate–severe AD more
frequently than those without any patch test reaction (P =
0.020). When the SCORAD score was evaluated in detail,
extent of eczema, score of sleep loss, and pruritus were
significantly higher for the patients with NS sensitization
than those without any reaction, as well (P = 0.002, P =
0.001, and P = 0.002, respectively).
The patients with MCI and thimerosal sensitization,
which were the second and third most prevalent positive
patch test reactions in our study, were compared separately
with negative patch test reactions. There was no difference
in assessed variables between these 2 groups and the group
without any patch test reaction.

Table 2. Comparison of the patients with nickel sulfate sensitization and those without any patch test reactions. Data are shown as
percentiles (absolute numbers) or medians (interquartile ranges), and statistically significant data are shown in bold.
Patch test reactions

Negative (n = 89)

Nickel sulfate (+) (n = 17)

P

Age (months)

24 (12–58)

20 (6–52)

0.333

Age of AD onset (month)

9 (2–23)

2 (1–18)

0.213

Sex, male

56.2 (50)

58.8 (10)

0.840

Prenatal smoking

6.7 (6)

17.6 (6)

0.155

Current household smoking

52.8 (47)

47.1 (8)

0.664

Consumption of cow’s milk in the first year of life

32.6 (29)

41.2 (7)

0.493

Coexisting allergic disease (asthma, allergic rhinitis

31.8 (28)

17.6 (3)

0.241

Familial history of allergic diseases

22.5 (20)

5.9 (1)

0.184

Allergen sensitization

55.1 (49)

58.8 (10)

0.774

Food allergen

31.5 (28)

41.2 (7)

0.475

Inhalant allergen

30.3 (27)

23.5 (4)

0.773

IgE

37 (16–190)

92 (30–382)

0.076

Percent of eosinophils

3 (1–5)

4 (2–11)

0.070

Face

61.8 (55)

58.8 (10)

0.818

Trunk

22.5 (20)

52.9 (9)

0.016

Moderate–severe AD

58.4 (52)

88.2 (15)

0.020

Total SCORAD score

30 (16–43)

43 (27–59)

0.036

Extent of eczema (involved percent of total body surface)

4 (2–9)

14 (5–44)

0.002

Score of B symptoms

6 (3–9)

8 (4–11)

0.303

Score of sleep loss

1 (0–5)

6 (4–8)

0.001

Score of pruritus

6 (3–8)

8 (6–10)

0.002

Localization of eczema
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4. Discussion
In this study, children with AD were evaluated for the
prevalence of CAS and clinically relevant symptoms of
contact dermatitis. The patients with positive patch test
reactions had higher scores of sleep loss and pruritus than
those without any reaction. Furthermore, the patients with
NS sensitization had significantly higher SCORAD scores,
wider extent of eczema, higher scores of sleep loss and
pruritus, and a higher frequency of trunk involvement. These
may be taken into account as warning points for investigating
children with AD for possible contact sensitization.
In the literature, the frequency of contact sensitization
of children with AD was reported as 6.2% to 89% in
different countries worldwide (2–7). This wide range of
frequency may be due to the usage of different contact
allergen panels and inclusion of different age groups of
children in different studies. In our study, the positive
patch test reaction rate was 33.8%. The frequency in our
study was less than the frequency in some of the other
studies, and this may be attributed to the younger age of
our patients as compared to the ages of the children in
those studies (12,17).
The frequency of CAS has been demonstrated to be
higher in severe AD groups than those with mild and
moderate disease, both in adults and in children (5–7).
In the present study, although there was no relation
between contact sensitization and severity of AD, when
the components of the SCORAD index were evaluated,
scores of sleep loss and pruritus were significantly higher
in the patients with positive patch test reaction. GiordanoLabadie et al. (2), who used a European standard series
including 25 allergens as patch test material in children
with AD, found that the age of onset of AD and its severity
were not associated with CAS and symptoms of contact
dermatitis. In accordance with the study by Jacob et al.
(12), exposure to current household smoking did not
differ for allergic contact sensitization in our study group.
Other clinical characteristics were similar between the
groups with and without sensitization.
In their study, conducted with children with AD,
Giordano-Labadie et al. (2) demonstrated that the risk
of developing a contact allergy was significantly elevated
in children after the age of 5 years. In the literature,
prevalence of CAS is generally thought to increase with
age and environmental exposure (18). However, in our
study population, no statistically significant difference
was found for the frequency and pattern of CAS between
patients older or younger than 24 months of age, in
accordance with the results found by Fortina et al. (10).
Children younger than 2 years old may be sensitized to
contact allergens (10,19), even children as young as the
1-week-old infant that Fisher et al. reported (20). In our
study, of 17 patients younger than 6 months old, 7 were

sensitized, and of 69 patients younger than 2 years old, 27
were sensitized to 1 or more contact allergens.
In the literature, most studies stated NS as being
the most common contact allergen, at a frequency of
14.9%–59.1% in patients with positive patch test reactions
(2–3,5,7,17). Accordingly, in our study population, NS
was the most common positive reaction with a frequency
of 37.8% (17/45). NS sensitization was also shown to be
the most common contact allergen in a group of Turkish
children admitted to a tertiary hospital with complaints of
eczema (13). Ear piercing, which may be the main nickel
source, is a common tradition in Turkey that is performed
even in the first years of life. Other sources of nickel
may be wrist straps, snaps, belt buckles, nickel-releasing
clothing fasteners, and the use of cleansing products
containing nickel (3). To our knowledge, there are no data
available about the association of NS sensitization with the
severity and extent of AD in the literature. In our study
population, NS sensitization was significantly related to
moderate–severe AD, higher SCORAD score, wider extent
of eczema, trunk involvement, and higher scores of sleep
loss and pruritus when compared with children with other
sensitizations and without any sensitization. Similarly,
Fortina et al., who studied children with AD and other
types of eczema, demonstrated that the prevalence of NS
sensitization was higher among children with truncal and
widespread dermatitis (10).
In our study, the second most common sensitization
was to MCI, with a frequency of 6.7% (9/134) in the patchtested population. MCI is a chemical preservative that
can be found in infant products, such as wet wipes and
moisturizing creams. In different studies conducted with
children with eczema, the frequency of MCI was stated
as between 1.5% and 4.9% of the patch-tested population
(21–26). These studies also included children with AD,
but none of them were entirely composed of patients with
AD. Tosti et al. (27) found MCI as the third most common
sensitization in pediatric patients, including those with
and without AD, with a frequency of 7.3%. According
to the literature, it may be stated that MCI sensitization
is more frequent in younger patients (21–26). This high
frequency may be explained by the history of frequent use
of personal skin care products containing this ingredient,
especially by patients with eczema.
Sensitization to thimerosal is reported to be frequent
in different studies from different countries, with rates
varying from 1% to 37% (28–29). In studies conducted
with children with AD, the frequency of thimerosal
sensitization was reported as between 1.5% and 12.2% in
the patch-tested population (10,17,30). In our study, the
thimerosal sensitization rate was 5.2% (7/134). Thimerosal
(merthiolate) is an organic mercurial derivative widely
used as a preservative, which has been added to various
products for medical use, such as vaccines, solutions

1211

AKAN et al. / Turk J Med Sci
for intracutaneous skin testing, thimerosal-containing
antigenic extracts for hyposensitization therapy,
immunoglobulin preparations, cleansing solutions, and
topical medicaments (31). In Turkey it was sold as a skin
disinfectant in the past.
Mailhol et al. (6) patch-tested 641 children diagnosed
with AD with the 6 active components of their topical
AD treatment and with their current emollient, and they
found a positive reaction in 40 (6%) children. In their
study, while younger age at the time of study, onset of AD
before 6 months of age, and IgE sensitization were risk
factors for contact sensitization, sex and history of asthma
were not associated with the risk of sensitization to topical
AD treatment. In our study, 25.4% (34/134) patients tested
had contact sensitization to the test substances that may be
found in emollients, antiseptics, cosmetics, and toiletries.
No patient was sensitized to steroids like budesonide
and hydrocortisone-17-butyrate. Only 1 patient had
sensitization to tixocortol pivalate, but no clinically

relevant symptoms. These patients had more than 1
positive reaction on patch testing more frequently than the
participants with positive reactions to other materials that
were not in emollients. There was no difference in analyzed
clinical characteristics between the patients sensitized to
ingredients of emollients and those sensitized to other
materials on TRUE test or those without any sensitization.
There are some limitations of this study. The absence of
a control group consisting of children without AD makes
no data available for comparing the frequency of contact
sensitization of AD patients with the general population.
Additionally, there may be referral bias of a tertiary
care center with a patient population having relatively
refractory eczema.
In conclusion, the results of our study confirm the
necessity of performing patch tests in the management of
AD, especially for NS sensitization in children with severe
AD with a larger extent of eczema and trunk involvement.
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